Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

DenmarkBack to Denmark

Clinical trials in Do Not Edit

4 clinical trials in Do Not Edit, Denmark. Every trial is listed in the EU Clinical Trials Register and updated daily.

DenmarkOur site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)
Do Not Edit at a glance
4
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

4 trials in Do Not Edit

Open in trial search

Glomerulonephritis chronic

Recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Region Oestergoetland

Cystic fibrosis

Recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Systemic lupus erythematosus

Not yet recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Benzocaine
  • Sponsor:UCB Biopharma

Diffuse large B-cell lymphoma

Not yet recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in Denmark

The busiest research cities in the country

All 47 cities in Denmark

Clinical research in Do Not Edit

What the registry says about research in the country

01 Do Not Edit
Hemic and Lymphatic Diseases
In Do Not Edit, investigators are evaluating novel combination immunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The study examines whether adding epcoritamab to standard R-mini-CHOP improves treatment outcomes in elderly or frail individuals. Combination immunotherapy with epcoritamab Elderly and frail patient management Efficacy of R-mini-CHOP augmentation Safety profiling of novel agents The trial reflects a growing focus on hematologic malignancies within the city's limited but active research community.
Immune System Diseases
A randomized non‑blinded study in Do Not Edit investigates the impact of stopping versus continuing rituximab in patients with ANCA-associated vasculitis who are in stable remission. The goal is to determine relapse rates after therapy discontinuation. Rituximab maintenance vs discontinuation Relapse monitoring in vasculitis Patient quality‑of‑life assessment Long‑term remission strategies This research aims to optimize long‑term management of immune‑mediated vascular disease with minimal treatment burden.
Musculoskeletal Diseases
While current trials in Do Not Edit focus on hematologic and immune conditions, the research infrastructure remains poised to explore therapies for musculoskeletal disorders, leveraging the expertise of the sole investigator. Potential biologic treatments for arthritis Bone health in aging populations Inflammation pathways shared with immune diseases Future collaborative study designs Ongoing discussions aim to broaden the trial portfolio to include musculoskeletal disease research.
Neoplasms
The city's oncology efforts concentrate on improving outcomes for aggressive lymphomas, exemplified by the trial adding epcoritamab to chemotherapy for DLBCL. This work seeks to enhance response rates and durability of remission. Targeted antibody therapy in lymphoma Improving response in frail patients Comparative effectiveness of combination regimens Translational biomarkers for treatment success Although only two trials are active, they highlight a strategic emphasis on cutting‑edge cancer therapeutics.
Back to DenmarkAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.